Please try another search
For the six months ended 31 December 2020, CannpalAnimal Therapeutics Ltd revenues increased 9% to A$756K.Net loss decreased 47% to A$273K. Revenues reflect Research& Development tax refund increase of 5% to A$686K. Lowernet loss reflects Research & Development decrease of 22% toA$595K (expense), Share based payments decrease of 83% toA$11K (expense), Corporate and Administration costsdecrease of 49% to A$29K (expense).
Period Ending: | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Revenue | 0.76 | 0.07 | 0.7 | 0.05 |
Gross Profit | ||||
Operating Income | -0.27 | -1.19 | -0.51 | -1.3 |
Net Income | -0.27 | -1.19 | -0.51 | -1.3 |
Period Ending: | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Assets | 1.44 | 1.95 | 1.95 | 3.36 |
Total Liabilities | 0.09 | 0.33 | 0.33 | 0.14 |
Total Equity | 1.35 | 1.61 | 1.61 | 3.21 |
Period Ending: | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 12 Months |
Cash From Operating Activities | -0.5 | -1.39 | -0.89 | -1.81 |
Cash From Investing Activities | ||||
Cash From Financing Activities | 0 | |||
Net Change in Cash | -0.5 | -1.39 | -0.89 | -1.81 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review